New hope for elderly brain cancer patients: modified chemo schedule shows promise

NCT ID NCT07476794

Recruiting now Disease control Sponsor: Sunnybrook Health Sciences Centre Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is for people aged 65 and older with a newly diagnosed, aggressive brain cancer called glioblastoma that has a specific genetic marker (unmethylated MGMT) making standard treatment less effective. Researchers are testing a different way of giving the chemotherapy drug temozolomide after radiation, giving it daily for 5 days every 28 days for up to 6 cycles. The goal is to see if this modified schedule can help patients live longer and slow the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: temozolomide (chemotherapy)
What this could lead to: If successful, this modified dosing schedule could offer a better way to slow tumor growth and extend survival for elderly patients with this hard-to-treat brain cancer.
What could go wrong: This is a small, early-phase trial (118 participants) testing a different schedule of an existing drug, so the benefit may be modest. Side effects from chemotherapy remain a risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA

Contacts and locations

Locations

Sunnybrook Health Sciences Centre
RECRUITING

Toronto, Ontario, M4N3M5, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.